All In Biotech

Drug Trial Radar · NCT05305664

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in Germany

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Aug 19, 2022

Primary completion

Jan 28, 2025

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.

Conditions

  • Hyperlipoproteinemia(a)

Interventions

  • Pelacarsen (TQJ230) 80 mg s.c.Drug

    Pelacarsen (TQJ230) 80 mg s.c. Q4W

  • Corresponding PlaceboDrug

    Placebo to Pelacarsen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis ScheduleTime frame: Up to Week 52

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cloppenburg, Germany

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Villingen-Schwenningen, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Munich, Bavaria, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, Germany

  • Novartis Investigative Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Geilenkirchen, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.